Latest Commercialization News

BlueScope Steel reported a resilient $309 million underlying EBIT for 1H FY2025 despite depressed steel spreads, announcing a 30 cents per share interim dividend and extending its buy-back program. The company is targeting a $500 million incremental EBIT uplift by 2030 through cost initiatives and strategic growth projects.

Contact Energy reported a 12% rise in EBITDAF to $404 million for 1H25, driven by new geothermal assets and strategic contracts, while net profit fell 7% due to market volatility and acquisition costs.

Osteopore Limited has drawn down A$2 million from the first tranche of its redeemable convertible notes, using the proceeds to repay existing loans and support ongoing business activities.

Macarthur Minerals Limited reported a comprehensive loss of AUD 252,771 for Q4 2024, marking a sharp reversal from the prior year's profit. The company is navigating reduced exploration spending and strategic asset sales while facing ongoing funding challenges.

BMG Resources is ramping up its drilling efforts at the Abercromby Gold Project with assays from Phase 1 drilling imminent, aiming to expand its existing 518,000oz gold resource. Concurrently, a new drilling program is planned for the nearby Bullabulling Project following a major regional acquisition.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Tivan Limited has formalised a Resourcing Protocol Agreement with the Kimberley Land Council, setting a clear path to negotiate an Indigenous Land Use Agreement for its Speewah Project.

Mirvac's 1H25 results reveal a modest decline in EBIT and operating profit, yet the company signals strong growth prospects fueled by residential sales momentum, sustainable development, and strategic capital partnering.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.